Bluebird Bio Shareholders Get New All-Cash Offer From Private Equity
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 14 2025
0mins
Should l Buy ?
Source: Benzinga
Bluebird Bio Agreement Update: Bluebird Bio's stock is rising after an amended agreement with Carlyle and SK Capital Partners allows shareholders to choose between receiving $3.00 per share plus a contingent value right (CVR) or $5.00 per share in cash.
Market Reaction: Following the news, Bluebird's stock price increased by 50.3%, reaching $4.98, as the company prepares for the completion of the ongoing tender offer after receiving necessary regulatory approvals.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
